Skip to main content

TRESIBA FLEXTOUCH, TRESIBA PENFILL (Novo Nordisk Pharmaceuticals Pty Ltd)

Product name
TRESIBA FLEXTOUCH, TRESIBA PENFILL
Date registered
Evaluation commenced
Decision date
Approval time
234 working days (255)
Active ingredients
insulin degludec
Registration type
EOI
Indication

TRESIBA FLEXTOUCH, TRESIBA PENFILL (solution for injection) is now also indicated for the treatment of diabetes mellitus in adolescents and children from the age of 1 year.

Help us improve the Therapeutic Goods Administration site